Immune Pharmaceuticals Signs Agreement to Regain Worldwide Rights for Ceplene

NEW YORK, June 15, 2017 /PRNewswire/ — Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (‘Immune’) announced today that it has signed an agreement with Meda, a Mylan NV company (‘Mylan’) to repurchase assets relating to Ceplene, including the right to commercialize Ceplene in Europe and to…